Matthias Luz

Matthias Luz possesses extensive experience in the pharmaceutical and biotech industries, currently serving as the Head of Drug Development for CNS Gene Therapy at Asklepios BioPharmaceutical, Inc. since June 2023. As the Founder of ML Clinical Solutions since June 2020, Matthias has also held significant leadership roles, including Chairman of the Board of Directors at GABA Therapeutics, Inc. and Chief Medical Officer at DemeRx, Inc. and ATAI Life Sciences AG. Prior to these roles, Matthias held various senior leadership positions at MedGenesis Therapeutix Inc., PRA Health Sciences, Cardion AG, Knoll Pharmaceutical/Abbott Laboratories, and Hoechst Marion Roussel/Aventis Pharma. Matthias Luz earned a Doctor of Medicine (MD) from Heidelberg University and has further education from the Harvard T.H. Chan School of Public Health.